Bio
Steve is a San Diego-based Venture Partner with Versant Ventures and is also the acting CEO of Quanticell, a privately held drug discovery company focused on combatting cancer resistance. In addition, he serves on the Boards of Directors of Amira, Anaphore, and Furiex (FURX). From 2007 – 2010, Steve was CEO & President of Ambrx and helped this biologics company mature its drug portfolio and platform through deals with Pfizer, Merck, Lilly, and Merck-Serono. Steve served as President & CSO of Syrrx from 2002-2005, and led the company through its $270M acquisition by Takeda in 2005 and for several years post acquisition. Prior to joining Syrrx, Steve gained 12 years of R&D experience at Eli Lilly and Company as both a researcher and Director. Steve is a co-inventor of ten compounds that have entered the clinic including Viracept™, a marketed AIDS drug (1997 launch) and NesinaTM, a marketed diabetes drug (2010 launch). Chemist by training with BA degree from Columbia and PhD from Harvard
Career
|
Versant Ventures Management LLCVenture capital firm focused on making investments in the healthcare and biotechnology industries. |